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INTRODUCTION 
FIOCAUZ 
This report covers activities developed by Oswaldo Cruz 
Foundation/Bio-Manguinhos during the period froM August 1984 to 
May 1985, end of the project 3P-82-0225-03, Yellow Fever <Latin 
AMerica), International DevelopMent Research Centre, Canada. It 
is divided in three Main lines as described in the InteriM 
Report: 
(1. Stabilized vaccine: AMong candidate stabilizer substances 
1 
described in the InteriM Report were chosen sucrose and sodiuM 
glutaMate. Both substances were added to the eMbryo juice before 
lyoph(lization and results obtained have justified the use of an 
iMproved forMulation for Yellow Fever vaccine. 
2. Studies on stability of reconstituted vaccine were continued 
aLMLng to find a candidade diluent which would Maintain potency 
of diluted vaccine; 
3. Aspects regarding Yellow Fever vaccine production, aiMing to 
standardize its quality control; 
RESULTS 
Methods used during these studies were basically those described 
in the InteriM Report. Virus titrations were perforMed using 
Vero cells and a reference vaccine was included in all tests. 
1. Studies with st~bilized vaccine 
In this report "standard" Means the vaccine produced according to 
Methods described by Penna <1>, that is, a pure supernate of 
centrifuged eMbryos without any substances added to it. 
"Stabilized" refers to vaccine prrepared with stabilizers which 
forMulation will be described below. 
In the InteriM Report it was shown that several substances as 
sugars <sucrose, sorbitol> and aMinoacids <arginine, glycine, 
sodiuM glutaMate> when added to final bulk of yellow fever 
vaccine showed a protective effect on final product 
therMostab i l i t•,J. 
In addition, it was also shown that a reasonable quantity of 170 
virus could be extracted froM the sediMent of the centrifuged 
production bottles with 199 MediuM and that extra virus could be 
used to increase the voluMe of produced vaccine. 
According to these data, it was tried a new formulation for 
yellow fever vaccine. Sucrose and sodiuM glutaMate were chosen 
as stabilizers due to their availability in local Market and 
lower price. To forM the final bulk, they were added to a 
Mixture of eMbryo juice and resuspension of the sediMent in the 
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stabilizers 20%. This new~ stabilized vaccine ~ave an econoMy of 
50~ over the standard vaccine which utilized pure eMbryo Juice. 
Twelve lots of ~tabilized vaccine were prepared and control tests 
of final product. 
1.1. Physical~ cheMical and biological characteristics 
All control tests 
12 lots approved. 
content w•s not 
required by WHO> 
utilization. Data 
recomMended by WHO <2> were perforMed and all 
It ls iMportant to notice that protein nitrogen 
over 0~25 mg per human dose (Maximum limit 
in spite of sodium glutamate and 199 MediuM 
are shown in table 5. 
1.2. Losses during lyophilization cycles 
Losses observed in virus titre during lyophilization cycles were 
lower 111 i th the stabilized va~ ines suggesting that stab i 1 izers 
added to final bulk also have presented a protective effect on 
170 virus during that operatior )<table 2>. · 
1.3. fherMostability 
All 12 lots of stabilized vaccine were exposed at 37C durint two 
weeks and they lost in average 0~35 log of virus titre. This 
finding is in contrast with those obtained with standard vaccine 
which lost 1.92 log in averaga <table 4>. 
As recoMMended by WHO (2) a vaccine to pass thermostability test 
should lose no More than one log after two weeks of exposure at 
37C. Following this criterion~ all 12 lots of stabilized vaccine 
comply with the test while froM 23 lots of standard vaccine only 
two (8.7k) would pass it. Another point is that there is an 
increase in standard deviation <froM 0,25 to 0~63> and 
coefficient of variation (froM 4.38 to 16.9k) of the exposed 
standard vaccine while for the stabilized product, both standard 
deviationand coefficient of variation maintained the saMe levelp 
suggesting th~t \degradation phenomema which ocurrs at 37C are 
less varia~le with the stabilized vaccine.) Data are shown in 
table 4. 
-1.4. Titre of final product 
All 12 lots of the stabilized vaccine were over the liMit of 3 
log per huMan dose as required by WHO (2). However~ the titre of 
the stabilized lots were lower than the standard vaccines (table 
3) probably due to the dilution of eMbryo juice. 
2. Studies with reconstituted vaccine 
A nuMber of e>~periments were perforMed to continue the studies on 
170 virus stability in reconstituted vaccine. Vials of standard 
and stabilized vaccines were reconstituted and diluted with 
various diluents as recoMMended to contain 3 tb 4 log of virus 
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Table 6 shows results obtained with several candidates as 
diluents and · Lt can be seen that distilled water presented a 
higher capacity for 170 virus protection,. Maintaining its titre 
up to 6 hours of incubation at 37C. This finding was unexpected 
and deserved to be further explored. Table 7 presents data 
showing that 170 virus stability in distilled water is coMparable 
to that given by bovine seruM. Table 8 shows that distilled 
water is a good diluent for both standard and stabilized vaccines 
a~e 9 and tlgUre 3 show that several solutions presented 
poorer results than distilled water and that actually standard 
vaccine in~re,sed its titre.· 
3. Vaccine production quality control 
3.1. Titration of virus in production bottles: Table 1 shows 
results obtained during routine titration of 170 virus in bottles 
containing triturated chick eMbryos. Forty three harvests in a 
total of 1.087 bottles,. coMprehending about 50.000 eggs were 
exaMined. It can be seen that the eMbryo juice average titre is 
5.94 log per Ml,. with a standard deviation of 0.30. This results 
is siMilar to that obtained last year. 
3.2. Titre loss during lyophilization cycles 
To deterMine how Much virus was being lost during a 
lyoph i 1 izat ion c•.::1c le :o- saMples of f ina 1 bulk were titrated and 
coMpared with final product titre. Table 2 shows results 
obtained with lots of standard and stabilized vaccines and it can 
be seen that the standard vaccine loses an average of 0.52 log 
during a lyophilization cycle where as the stabilized one loses 
0.31 log. 
3.3. Titre of final product 
Table 3 shows titres of final 
those obtained with standard 
stabilized one. All produced 
established by WHO of 3 logs per 
3.4. TherMostability 
product and it can be 
vaccine were higher 
lots had titers over 




Vaccine therMostability tests were perforMed according to the 
Method recomMended by WHO <2>. Vials of dried vaccine were 
exposed during two weeks at 37C and titrated using flasks of the 
same lot kept at -20C ~s controls. Results are shown in table 4 
and figure 1 and it can be seen that standard vaccines lose 1.55 
log in average after two weeks of exposure at 37C~ being this 
results similar to that shown in the Interim Report. On the 
other hand,. stabilized vaccines lose 0.35 log in average. 
3.5. Identity 
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.-;: ·, ... -~'-> : 
FIOCAUZ;. 
Yellow Fever. vaccine as Lt was be~ng produced by Bio-· 
Manguinhos/Oswaldo Cruz Foundation, Ln spite of several 
technological iMproveMents, followed techniques described in 1954 
by Penna <1>. 
The standard vaccine, which coMplied with requireMents Ma~e by: ~ 
WH0<2>, presented a low therMostability, which shortened its 
shelf life and was unstable after reconstitution with saline. 
TherMost&b i-l i t'Y -resul ts~·presented~i-n --Table ·-4 showed-tha-t ·-standard·-· · --- -
vaccine lbst· 1.95 log of its titer after exposure at 37C during 
two weeks as retoMMended by WHO <2>. Actually, froM 23 standard 
vaccine lots studied, only 2 (8.7X> would be approved in this · 
test. Moreover, reconstituted standard vaccine, in spite of 
Maintaining its titer when kept in lee-bath, presented a rapid 
inactivation when exposed at 37C. These characteristics, that 
ls, a low therMostabillty.of the dry product and the instability 
of reconstituted vaccine should be Modified due to the fact that 
this vaccine is used in rural areas where the cold chain ls not 
always reliable and vaccinacion is usually perforMed under high 
aMbient teMperatures. -
~y these reasons, tha Main objectives of this project were to 
tMprove Yellow Fever vaccine in both aspects. In order to 
achieve theM, it was necessary to standardize 170 virus titration 
in Vero cells and to Maintain a continuous quality control 
process for vaccine production. 
Aspects and preliMinary results were reported in the InteriM 
Report and have continued to be done during the present period •. -
Following this line of work, it was deterMlned virus content in 
infected eMbryo Juice, <table 1)7 losses that occurred during a 
l~Ll.i..~~.t...!E!!..~~<=~.le <table 2> and-therMostab i.1 i ty (table 4). 
Other pare.Meters- as potency (tiibie-~and raent1 ty were also 
deterMined and it can be seen that standard vaccine coMplies 
with WHO requireMents for Y-ellow Fever vaccine <2>, with the 
exception of therMostability. 
The second part of this study aiMed to find ~ suitable diluent to 
reconstitute and dilute Yellow Fever vaccine. Since the 
beginning of __ j~eJ_!Q!L_Fever vaccine production <t>~ the recoMMended 
diluent was~~15 M ~~11n::_g?, which is being used for alMost all 
production laboratories. 
SoMe tests reported Jn the InteriM Report showed that vaccines 
reconstituted with saline were able to Maintain their virus titre 
only if held in ice both while those incubated at 37C lost their 
titre in less than one hour. 
It was found that vaccine reconstituted and diluted with 
distilled water would Maintain the virus titre during incubation 
at 37C for at least 6 hours <tables 6, 7 and 8) and this 
phenoMenoM occurred with bath stabilized or standard vaccines. 
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stability of Yellow Fever virus suspended in distilled water (3). 
It was a work done ln 1930 with no conclusive results on the 
action of this·substance when used to dilute rhesus Monkey seruM 
or Mosquitoes containing Yellow Fever virus to be filtered 
through Berkfeld candles. 
(Yellow Fever vaccine reconstituted and diluted wlth distilled 
water retained its titer for at least 6 hours incubation at 37C 
<table 6) and it was shown that the titre of the virus was 
siMilar to others diluents containing seruM <table 7) and these 
results were observed with both types of vaccine <table 8). It 
can be co~cl~ded that Yellow Fever vaccine can be reconstituted 
and dituted with distilled water and will be able to retain 
its titer when exposed at 37C for 6 hours at least. The reasons 
why distilled water is the best diluent for Yellow Fever vaccine 
produced at Oswaldo Cruz Foundation reMaln unknow up to this 
MOMent. 
Concerning vaccine stability. several substances have been added 
to the final bulk before lyophilization aiMing at an iMproveMent 
of its therMostability. Besides. it was also found that a 
signif icative aMount of 170 virus could be· recovered froM the 
sediMent of bottles centrifuged to obtain eMbryo juice. The 
protective action of those substances and virus extraction froM 
sediMent were described in InteriM Report. 
AMong substances candidate as stabilizers. it was chosen sucrose 
and sodiuM glutaMate. due to their availability and price. To 
prepare stabilized vaccines. sucrose and sodiuM glutaMate and a 
resuspension of sediMent were added to eMbryo juice in 
proportions already described. 
Twelve lots of this vaccine were prepared and obtained results 
showed that their cheMical. physical and biological 
characteristics coMplayed with requireMents issued by WHO <2> and 
data are shown in tables 3 and 5. Moreover. the therMostability 
of this stabilized vaccine was better than that observed with 
standard vaccine as all 12 prepared lots lost less than 0.5 log 
of virus titre after exposure at 37C <table 4). 
In conclusion. the three Main lines of project JP-82-0225-03 were 
accoMplished with success. A titration Method for 170 virus 
using Vero cells was standardized and it is being used to control 
production and final product. a new improved yellow fever vaccine 
with a good thermostability is being produced and a suitable 
diluent was found. All these probleMs had to be solved due to 
the characteristics of Yellow Fever vaccination which is utilized 
in rural areas of tropical countries where the cold chain is not 
reliable and vaccination is perforMed under high ambient 
teMperatures. (Besides~ this new formulation allows an econoMy of 
50% on the use of infected eMbryos~ giving an increase of the 
production that combined with an enlargeMent of its shelf life 
allows to build up a strategic stock to face epideMics in rural 
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1. Penna, H.A. WHO Monograph Series n. 30, 1954 pp. 67-90. 
2. WHO Technical Report Series n. 594, 1976. 
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TABLE 1 
YELLOW FEVER VACCINE. TITRATION OF BOTTLES CONTAINING EMBRYO PULP 
PROD # DATE QUANTITY OF AVERAGE STANDARD COEFFICIENT 
BOTTLES TITRE DEVIATION OF VARIABILITY 
29 04-06-84 20 6.05 0,23 3.80 
30 11-06-84 20 5.11 0,16 3.08 
32 14-06-84 21 6.22 0,16 2.51 
34 25-06-84 30 6.21 0,25 4.13 
35 28-06-84 28 6.13 0,18 3.04 
36 02-07-84 28 6.24 0,20 3.33 
37 05-07-84 27 6.01 0,19 3.28 
38 09-07-84 29 5.99 0,16 2.74 
39 16-07-84 28 6.04 0,17 2.94 
40 19-07-84 21 6.26 0,19 3.07 
41 23-07-84 28 5.75 0,18 3.20 
42 26-07-84 20 5.94 0,11 3.90 
43 30-01-84 18 5.93 0,17 2.90 
44 06-08-84 20 6.16 0,12 1.94 
45 13-08-84 27 6.12 0,15 2.51 
46 16-08-84 28 6,02 0,13 2.20 
48 23-08-84 28 5.46 0,14 2.55 
49 27-08-84 28 5.50 0,14 2.64 
50 30-08-84 26 6.02 0,16 2.70 
51 03-09-84 27 6.10 0,12 1.90 
52 06-09-84 26 6.11 0,20 3.42 
53 13-09-84 28 6.13 0,18 2~93 
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1087 bottles 25.2 
TITRES EXPRESSED AS LOG PER ML. 
FIOCRUZ 
AVERAGE STANDARD COEFFICIENT 
TITRE DEVIATION . OF VARIABILITY 
6.14 0,17 2.73 
6. 14 -- - - 0' 20-- -. 3. 21 . 
6.21 0,15 2.41 
6.24 0,16 2.53 
6.26 0,19 3.00 
6.29 0,14 1.46 
6.18 0,16 2.58 
6.12 0,18 2.91 
5.81 0,22 3.87 
6.11 0,18 3.84 
6.13 0,13 2.23 
5.25 0,20 3.91 
5.32 0,16 3.10 
5.85 0,13 2.31 
5.83 0,16 2.77 
5.79 0,15 2.62 
5. 5.1 0,16 2.95 
5.65 0., 26 4.69 
5.60 0,20 3.60 
5.62 0,19 3.37 
5.94 0,30 5.05 
I 
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I STANDARD AND STABILIZED YELLOW FEVER VACCINE. TITRES BEFORE AND AFTER LYOPHILIZATION 
STANDARD VACCINE STABILIZED VACCINE 
VACCINE TITRE VACCINE TITRE LOSS LOSS 
LOT BEFORE AFTER LOT BEFORE AFTER 
35 6.18 5.80 0,38 41 5. 46. 5.13 0,33 
36 6.21 5.86 0,35 44 5.48 5.08 0,40 
37 5.95 5.03 0,92 50 5.58 5.24 0,34 
38 6.10 5.22 0,88 65 5.97 5.70 0,27 
39 5.96 5.21 0,75 68 5.84 5.46 0,38 
4o· 5.65 5.14 0,51 71 5.87 5.51 0,36 
43 5.84 5.34 0,50 72 5.35 5.14 0,21 
49 6.17 5.55 0,62 74 5.20 4.90 0,30 
51 5.63 5.17 0,46 77 5.72 5.49 0,23 
52 6.32 5.78 0,04 
54 5.95 5.50 0,45 Mean 5.60 5.29 0,31 
Standard 
55 6.24 5.82 0,42 deviation 0.28 0,27 
56 5.47 5.02 0,45 coef ficent 
bf 
57 6.48 6.07 0,41 variation 5.00% 5.18% 
60 6.47 6.07 0,37 
61 5.95 5.56 0,39 
62 6.27 5.86 0,41 
Mean 6.04 5.52 0,52 
Standard 0.28 0.36 
devia,tion 
Coeff icent 4.73% 6.53% 
of 
ariability 
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TABLE 3 
FIOCRUZ 


















.Log per humin.-,. 
3.00 - 3.20 
3.21 - 3. 40 
3.41 - 3.60 
3.61 - 3.80 
3.81 - 4.00 
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TABLE 4 
STANDARD AND STABILIZED YELLOW FEVER VACCINE. RESULTS OF THERMO-
STABILITY TESTS AS RECOMMENDED BY WHO.Cl) 
STANDARD VACCINE STABILIZED 
. 
TITRE (x) TITRE 
Lot Before ~fter(x) Loss Lot Before 
35 5.31 (x) 4.17 1.14 41 5.55 
36 5.40 4.65 0.75 44 5.30 
3 ], 5.51 3.75 1. 74 46 5.21 
38 5.30 3.69 1. 61 48 5.54 
39 5.59 4.25 1. 34 50 5.68 
40· 5.73 4.30 1.43 65 5.63 
42 5.59 4.50 1. 09 68 5.45 
43 5.82 5.00 0.82 69 5.20 
45 5.78 3.74 2. 04. 70 4.92 
47 5.57 4.07 1. 50 71 5.11 
49 6.04 4.30 1. 74 72 5.42 
51 6.11 3.84 2.27 73 5.09 
52 5.60 2. 70 . 2.90 
53 5.77 2.51 3.26 Mean 5.34 
54 5.88 2.86 3.02 SD 0.24 
55 6.00 4.02 1. 98 CV 4.48% 
56 5.67 3.00 2.67 
57 5.63 3.54 2.09 
58 5.78 3.24 2.54 
60 5.75 3.17 2.58 
61 5.84 3.87 1. 97 
62 5.98 3.67 2.31 
67 5.12 3.57 1. 57 
Mean 5.68 3.75 1. 92 
SD 0.25 0.63 -
CV 4.38% 16.9% -
SD= Standard deviation; CV= Coefficient of variation· 
(1) TRS . 594, 1976 
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TABLE 5 
PHYSICAL, CHEMICAL AND BIOLOGICAL CHARACTERISTICS OF STABILIZED 
YELLOW FEVER VACCINE 
VACCINE POTENCY % RESIDUAL PROTEIN AVERAGE STERILITY INNOCUITY IDENTITY .. LOT . . HUMIDITY NITROGEN WEIGHT 
. . 
41 :3.44 2.00 . 0,14 . 80. 77 ok ok ok 
.. 
.. 
.. 44 3.38 1.81 0,14 77 .40 ok ok ok 
. . 
.. 46 .3.69 1.48 0,17 84.65 ok ok ok 
.. 
~8 3.52 1.69 0,21 75.67 ok ok ok 
50 3.44 1.48 0,22 73.75 ok ok ok 
65 4.0 1.68 0,15 76.70 ok ok ok 
68 3.76 1.65 0,15 70.83 ok ok ok 
.. 
69 3.43 2.29 0,13 79. 71 ok ok ok 
70 3.25 2.39 0,14 72.90 ok ok ok 
71 3.85 2.46 0,14 79.05 ok ok ok 
72 3.44 2.17 0,13 74.21 ok ok ok 
73 3. 72 2.06 0,16 75.09 ok ok ok 
Potency expressed as log per human dose. 
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TABLE 6 
FIOCRUZ 
STABILITY OF RECONSTITUTED YELLOW FEVER VACCINE INCUBATED IN 
ICE BATH AND 379C 
I~ 
: PBS PBS PLUS GELATINE PBS PLUS GEL I SATE DISTILLED WATER 
- 379 c ICE BATH 379C ICE BATH 379C ICE BATH 379C ICE BATH N 
. 
* Initial 4.00 4.00 4.36 4.36 4.10 4.10 4.12 4.12 
** 3 hours - 4.02 2.00 4.00 1.50 4.16 3.65 4.24 
6 hours - 4.25 - 4.27 - 4.50 3.81 4.33 
* Titres expressed as log per human dose 
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TABLE 1 
FIOCAUZ 
I I STANDARD YELLOW FEVER VACCINE. STABILITY OF RECONSTITUTED VACCINE AT 














1 hour 3.69 
3 hours 3.91 
DISTILLED WATER 
WITH WITH 
GEL I SATE GELATIN 
2% 2% 
* 3.82 3.79 
3. 71 3.02 
3.24 2.17 
I * Titres expressed as log per human dose 















P B S 
WITH WITH WITH 
GEL I SATE GELATIN SERUM 
2% 2% 2% 
3.76 3.60 3.91 
2.09 2.94 4.12 
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I ·TABLE 8 


















VACCINE IN DISTILLED WATER INCUBATED IN 379C AND ICE B~TH 
VACCINE BEGINNING. 3 hours in 3 hours 
ice bath at 379C 
01 3.63 (x) 4.08 3.55 . 
36 4.00 3.97 3.40 
44 3.54 3.51 3.25 
65 3.90 3.86 32 7 
(x) Titers expressed as log per human dose 
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TABLE 9 
FIOCRUZ 
YELLOW FEVER VACCINE. LOSS OR GAIN IN TITRE OF STABILIZED AND 
STANDARD VACCINES RECONSTITUTED WITH VARIOUS DILUENTS AFTER 
~NCUBATION AT 379C DURING 3 HOURS 
DILUENT STANDARD VACCINE STABILIZED VACCINE 
Distilled water + 0,40 - 0,04 
0,15 M Saline - 1,29 - 0,86 
0,03 M Saline - 0,30 - 0,33 
O,OOlM Sucrose - 1,40 - 0,49 
0,01 M Glutamate - 1,27 - 1,03 
0,01 M Arginine - 1,62 - 1,49 
Sucrose plus Glutamate - 1,27 ..... 1,34 
Sucrose plus Arginine - 1,37 - 1,47 
Glutamate plus Arginine - 1,58 - 1,03 
MONO-LOO 
-.., .:..-; ~ ,, M 9- rri ~r . 
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DATA RE CE I TA 
29 .09.83 - Importancia recebida; conf. Aviso de 
Credito 3916066 de 22.09.83 e deposi 
tado na c/c 71.556-5 do Banco do J 
Brasil S/A 
14.02.85 - Importancia recebida conf. Aviso de 
Credito 3916540 de 11.02.85 e deposi 





JOS~ CARLOS SANTIAGO 
Gerente Servi~o de Contabilidade 
Contador CRC - 020.108-6 
MISC/ajmr. 
CO~NIO CENTRO INTERNACIONAL DE PESQUISAS 
PARA 0 DESENVOLVIMENTO -. CANADA 
P'ROJETO: FEBRE AMARELA (~RICA LATINA) 
ROSiyAO EM: 12.06.85 
·-· 
, D. E s 
MATERIAL DE CONSUMO 
EMPENHADOS NO ANO DE 1984 --
Material Grafico 
Material de Escritorio 
927.535 




Rio de Janeiro, 12 de junho de 1985 
. 
_,._ 
p E · S A 
TOTAL 
A PAGAR PAGO 
- 744.240 -
- 112 .101 856.341 
4. 5'41. 744. - 4.541.744 
- - 5.398.085 
I 
C rC:O.l----- ~~ 
·-.. D~. AfUR) HOMMA 
Superintendente c e Bio-Manguinhos 
-. 
--- -----------~--~-.,----- --- -- ----- --- -----------------------
D A T E 
28.09.83 
14.02.85 
T 0 T A L 
BUDGET 
FIOCRUZ ADMINISTERED FUNDS (IN CRUZEIROS) 
FUNDS RECEIVED FROM IDRC IN CANADIAN DOLLARS 
EXPENSES 
F U N D s 
CONSUMABLE SUPPLIES 
Received from IDRC by credit bill 3916066 1984 -
and deposited at Banco do· Brasil acc01.mt Graphic materials 
in 71.556-5 ·················•••4!••4!••111•••.• 927.535 Off ice materials 
Received from IDRC by credit bill 3916540 . 1985 --
a;n.d deposited at Banco do Brasil account Several off ice materials 
in 71.556-5 ·····~·····~••«!••,······~······· 4.470.550 
.5.398 •. 085 T 0 T A L 
Rio de Janeiro, 12 de junho de 1985. 
TOTAL 
TO BE PAID PAID 
- 744.240 -
- 112.101 856.341 
4.541. 744 - 4.541.744 
- - 5.398.085 
